Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-cash Items (2023 - 2025)

NewAmsterdam Pharma's Non-cash Items history spans 3 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Non-cash Items fell 96.62% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, down 96.62%, while the annual FY2025 figure was $10.1 million, 96.62% down from the prior year.
  • Non-cash Items for Q4 2025 was $10.1 million at NewAmsterdam Pharma, roughly flat from $10.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $298.0 million in Q4 2024 and bottomed at $5.2 million in Q4 2023.
  • The 3-year median for Non-cash Items is $10.1 million (2025), against an average of $104.7 million.
  • The largest annual shift saw Non-cash Items skyrocketed 5596.88% in 2024 before it tumbled 96.62% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $5.2 million in 2023, then surged by 5596.88% to $298.0 million in 2024, then crashed by 96.62% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Non-cash Items are $10.1 million (Q4 2025), $10.1 million (Q3 2025), and $141.1 million (Q2 2025).